Cart  

No products

Shipping 0,00 €
Total 0,00 €

Cart Check out

Manufacturers

Search

CIMALGEX ® 80mg 144 pills

CIMALGEX ® 80mg 144 pills
For the treatment of pain and inflammation associated with osteoarthritis, and the management of peri-operative pain due to orthopaedic or soft tissue surgery, in dogs. Precription required. Please send a message of your prescription using contact button and attach your digitalization or photo of your prescription.

More details

213,25 €

L01B0168

Add to cart

Cimalgex chewable tablets for dogs

Presentation

Cimalgex 80mg chewable tablets for dogs

Oblong, white to pale brown, chewable tablets with a break-line on both sides.

The tablets can be divided into equal halves.

Uses

For the treatment of pain and inflammation associated with osteoarthritis, and the management of peri-operative pain due to orthopaedic or soft tissue surgery, in dogs.

Dosage and administration

Oral use.

Cimalgex tablets can be administered with or without food. The tablets are flavoured and studies (in healthy Beagle dogs) show they are likely to be taken voluntarily by most dogs.

The recommended dose of cimicoxib is 2 mg per kg bodyweight, once daily, according to the dosage table below:

Bodyweight of dog (kg)

Number of Tablets and Tablet Strength

(mg cimicoxib)

Cimalgex 8 mg

Cimalgex 30 mg

Cimalgex 80 mg

3.0 - 4.0

1

 

 

4.1 - 7.5

 

½

 

7.6 - 15.0

 

1

 

15.1 - 20.0

 

 

½

20.1 - 40.0

 

 

1

40.1 - 60.0

 

 

1 +½

>60.1

 

 

2

Treatment duration:

Management of peri-operative pain due to orthopaedic or soft tissue surgeries: one dose 2 hours prior to surgery, followed by 3 to 7 days of treatment, based on the judgment of the attending veterinarian. Relief of pain and inflammation associated with osteoarthritis: 6 months. For longer-term treatment, regular monitoring should be undertaken by the veterinarian.

Contra-indications, warnings, etc.

Do not use in dogs less than 10 weeks of age.

Do not use in dogs suffering from gastrointestinal disorders or haemorrhagic disorders.

Do not use concomitantly with corticosteroids or other non-steroidal anti-inflammatory drugs (NSAIDs).

Do not use in case of hypersensitivity to cimicoxib or to any of the excipients.

Do not use in breeding, pregnant and lactating animals.

Special Warnings: None.

Special precauctions for use in animals:

Since the safety of the medicinal product has not been adequately demonstrated in young animals, careful monitoring is advised during the treatment of young dogs aged less than 6 months.

Use in animals suffering from impaired cardiac, renal or hepatic function, may involve additional risk. If such use cannot be avoided, these animals require careful veterinary monitoring.

Avoid using this product in any animals which are dehydrated, hypovolaemic or hypotensive, as it may increase the risk of renal toxicity.

Use this veterinary medicinal product under strict veterinary monitoring where there is a risk of gastrointestinal ulceration, or if the animal previously displayed intolerance to NSAIDs.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Cimicoxib may cause skin sensitisation. Wash hands after use.

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

People with a known hypersensitivity to cimicoxib should avoid contact with the veterinary medicinal product. Administer the veterinary medicinal product with caution.

Adverse reactions (frequency and seriousness)

Mild and transient gastro-intestinal disorders (vomiting and/or diarrhoea) were very commonly reported.

On rare occasions, serious gastrointestinal disorders such as haemorrhage and ulcer formation have been noted. Other adverse reactions including anorexia or lethargy may also be observed on rare occasions.

In very rare cases, increases in renal biochemistry parameters were noted. As for any long term NSAID treatment, renal function should be monitored.

If any observed adverse effect persists after stopping treatment, the advice of a veterinarian should be sought.

If adverse reactions such as persistent vomiting, repeated diarrhoea, faecal occult blood, sudden weight loss, anorexia, lethargy or worsening of renal or hepatic biochemistry parameters occur, use of the product should be discontinued and appropriate monitoring and/or treatment should be put in place.

Use during pregnancy, lactation or lay

Do not use in breeding, pregnant or lactating bitches. Although no data are available in dogs, studies with laboratory animals have shown effects on their fertility and foetal development.

Interaction with other medicinal products and other forms of interaction

Cimalgex should not be administered in conjunction with corticosteroids or other NSAIDs. Pre-treatment with other anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed before the commencement of treatment with Cimalgex. The treatment-free period should take into account the pharmacokinetic properties of the veterinary medicinal product used previously.

Overdose

In an overdose study where 3 times (5.8 to 11.8 mg/kg body weight) and 5 times (9.7 to 19.5 mg/kg body weight) the recommended dose was administered to dogs for a period of 6 months, a dose related increase in gastrointestinal disturbances, which affected all dogs in the highest dose group, was noted.

Similar dose related changes to haematology and white blood cell counts, as well as renal integrity, were also noted.

As with any NSAID, overdose may cause gastrointestinal, kidney, or liver toxicity in sensitive or compromised dogs.

There is no specific antidote to this product. Symptomatic, supportive therapy is recommended consisting of administration of gastrointestinal protective agents and infusion of isotonic saline.

Withdrawal period

Not applicable.

Pharmaceutical precautions

Shelf life of the veterinary medicinal product as packaged for sale: 3 years. Any remaining half tablets should be discarded after 2 days storage in the blisters. Any remaining half tablets should be discarded after 90 days storage in the bottle.

This veterinary medicinal product does not require any special storage conditions.

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

Any half tablets should be stored in the blister pack/bottle.

No customer comments for the moment.

Only registered users can post a new comment.